click on circles to display study description...

Chaccour, 2020 NCT04390022

ivermectin (n=12) vs. placebo (n=12)

randomized controlled trial

ivermectin
400 mcg/kg, single dose

placebo

COVID-19 mild to moderate

double bliind

1 center, Spain

Kirti, 2021 CTRI/2020/08/027225

ivermectin (n=57) vs. placebo (n=58)

randomized controlled trial

Ivermectin
ivermectin 12 mg on day 1 and day 2

Placebo

COVID-19 mild to moderate

All patients above the age of 18 admitted with a diagnosis of COVID -19 (on the basis of a positive RT PCR or Rapid Antigen Test report) at AIIMS, Patna, India with mild or moderate disease as defined by the ministry of health and family welfare guidelines and not meeting any of the exclusion criteria were considered eligible for the study. The exclusion criteria were: known allergy to or adverse drug reaction with Ivermectin; unwillingness or inability to provide consent to participate in the study; prior use of ivermectin during the course of this illness; pregnancy and lactation.

Double-blind.

Single center, tertiary care dedicated COVID-19 hospital in Bihar, India.

Krolewiecki, 2020 NCT004381884

ivermectin (n=30) vs. standard of care (n=15)

randomized controlled trial

Ivermectin
Standard of care plus oral ivermectin at 0.6 mg/kg/day for 5 days.

Standard of care

All patients in both groups received standard of care.

COVID-19 mild to moderate

Eligibility criteria included COVID-19 symptoms onset ≤ 5 days at recruitment, absence of use of drugs with potentialactivity against SARS-CoV-2 and available in Argentina during the trial (hydroxychloroquine, chloroquine, lopinavir and azithromycin); and those drugs were not permitted during the first week of the trial.

Open-label.

4 hospitals in the metropolitan area of Buenos Aires, Argentina.

I-TECH (Lim), 2022 NCT04920942

ivermectin (n=241) vs. standard of care (n=249)

randomized controlled trial

oral ivermectin, 0.4 mg/kg body weight daily for 5 days, plus standard of care

standard of care alone
symptomatic therapy and monitoring for signs of early deterioration based on clinical findings, laboratory test results, and chest imaging.

COVID-19 mild to moderate

open-label

Malaysia

Shahbaznejad, 2020 IRCT20111224008507N3

ivermectin (n=35) vs. standard of care (n=38)

randomized controlled trial

Ivermectin
Single dose of 0.2 mg/kg

Standard of care
Standard drugs of the national protocol are used.

All patients in both groups received supportive medical treatment for COVID-19 according to the national protocols of Iran at the time of this study (hydroxychloroquine and/or lopinavir/ritonavir).

COVID-19 mild to moderate

The diagnostic criteria for COVID-19 included any of the following: (1) positive result on COVID-19 reverse-transcription polymerase chain reaction; (2) clinical symptoms of COVID-19, with a history of contact with a patient with COVID-19; and/or (3) abnormalities on chest computed tomography (CT) compatible with COVID19 (ground-glass opacity, halo sign, reversed halo sign, and patchy infiltration).

Double-blind.

2 centers in Mazandaran, Iran.

Clinical improvement after baseline was defined as resolving a patient’s baseline status on persistent and continuous cough (persistent cough for >1 hour, or ≥3 coughing episodes in 24 hours, that interferes with activities of daily living and the ability to work) and tachypnea in addition to increasing oxygen saturation to >94%.

NCT04523831 (Mahmud), 2020 NCT04523831

ivermectin plus doxycycline (n=200) vs. standard of care (n=200)

randomized controlled trial

Ivermectin and Doxycycline
Ivermectin 6 mg, 2 tab stat and Doxycycline 100 mg twice daily for 5 days

standard of care

COVID-19 mild to moderate

double blind

1 center, Bangladesh